Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma
- PMID: 23103770
- DOI: 10.1016/j.bbcan.2012.10.002
Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies, and is also the fourth most common cancer worldwide with around 700,000 new cases each year. Currently, first line chemotherapeutic drugs used for HCC include fluorouracil, cisplatin, doxorubicin, paclitaxel and mitomycin, but most of these are non-selective cytotoxic molecules with significant side effects. Sorafenib is the only approved targeted therapy by the U.S. Food and Drug Administration for HCC treatment, but patients suffer from various kinds of adverse effects, including hypertension. The signal-transducer-and-activator-of-transcription 3 (STAT3) protein, one of the members of STATs transcription factor family, has been implicated in signal transduction by different cytokines, growth factors and oncogenes. In normal cells, STAT3 activation is tightly controlled to prevent dysregulated gene transcription, whereas constitutively activated STAT3 plays an important role in tumorigenesis through the upregulation of genes involved in anti-apoptosis, proliferation and angiogenesis. Thus, pharmacologically safe and effective agents that can block STAT3 activation have the potential both for the prevention and treatment of HCC. In the present review, we discuss the possible role of STAT3 signaling cascade and its interacting partners in the initiation of HCC and also analyze the role of various STAT3 regulated genes in HCC progression, inflammation, survival, invasion and angiogenesis.
Copyright © 2012 Elsevier B.V. All rights reserved.
Similar articles
-
Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3.Mol Oncol. 2015 Apr;9(4):818-33. doi: 10.1016/j.molonc.2014.12.008. Epub 2015 Jan 5. Mol Oncol. 2015. PMID: 25624051 Free PMC article.
-
Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.J Cell Physiol. 2012 May;227(5):2184-95. doi: 10.1002/jcp.22954. J Cell Physiol. 2012. PMID: 21792937
-
Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.Int J Mol Med. 2013 Jul;32(1):79-84. doi: 10.3892/ijmm.2013.1358. Epub 2013 Apr 22. Int J Mol Med. 2013. PMID: 23613111
-
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.World J Gastroenterol. 2014 Nov 7;20(41):15269-74. doi: 10.3748/wjg.v20.i41.15269. World J Gastroenterol. 2014. PMID: 25386075 Free PMC article. Review.
-
[Review on the associations of signal transducer and activators of transcription 3 with hepatocellular carcinoma].Zhonghua Yu Fang Yi Xue Za Zhi. 2016 May;50(5):468-72. doi: 10.3760/cma.j.issn.0253-9624.2016.05.017. Zhonghua Yu Fang Yi Xue Za Zhi. 2016. PMID: 27141908 Review. Chinese.
Cited by
-
Optimization of Taste-Masked (-)-Oleocanthal Effervescent Formulation with Potent Breast Cancer Progression and Recurrence Suppressive Activities.Pharmaceutics. 2019 Oct 5;11(10):515. doi: 10.3390/pharmaceutics11100515. Pharmaceutics. 2019. PMID: 31590382 Free PMC article.
-
Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection.BMC Cancer. 2022 Mar 7;22(1):249. doi: 10.1186/s12885-022-09345-2. BMC Cancer. 2022. PMID: 35255845 Free PMC article.
-
Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication.Front Oncol. 2019 Feb 21;9:48. doi: 10.3389/fonc.2019.00048. eCollection 2019. Front Oncol. 2019. PMID: 30847297 Free PMC article. Review.
-
Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway.Cancers (Basel). 2021 Oct 31;13(21):5479. doi: 10.3390/cancers13215479. Cancers (Basel). 2021. PMID: 34771643 Free PMC article.
-
Ellagic Acid Holds Promise Against Hepatocellular Carcinoma in an Experimental Model: Mechanisms of Action.Asian Pac J Cancer Prev. 2018 Feb 26;19(2):387-393. doi: 10.22034/APJCP.2018.19.2.387. Asian Pac J Cancer Prev. 2018. PMID: 29479987 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous